A TCGA study of 363 HCC samples found a low B-RAF mutation prevalence of 0.3%, indicating that while B-RAF mutations are not a primary driver of HCC, they may still contribute to tumor biology in select cases [20]. This evidence concerns the gene BRAF and neoplasm.